A 16 Week Study to Evaluate the Efficacy and Safety of PF-06882961 in Adults With Type 2 Diabetes Mellitus
A 16 Week Study to Evaluate the Efficacy and Safety of PF-06882961 in Adults With Type 2 Diabetes Mellitus. A 16-Week, Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Twice Daily PF-06882961
Administration in Adults With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin or
Diet and Exercise.
Category & Conditions: Diabetes and Metabolic Disorders
Medicine: danuglipron (PF-06882961)
ClinicalTrials.gov Identifier (NCT): NCT03985293
Protocol ID: C3421005
PrintDownloadOpen Plain Language Summary Result: Click here